RTP Mobile Logo
Cases from the Community: Clinical Investigators Provide Their Perspectives on Emerging Research and Actual Patients with Ovarian Cancer
Released May 2018

Proceedings from an independent satellite symposium during the Society of Gynecologic Oncology’s 2018 Annual Meeting on Women’s Cancer. Featuring perspectives from Drs Don S Dizon, Lainie P Martin, Bradley J Monk and Angeles Alvarez Secord. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

    The American Cancer Society estimates that in 2018, approximately 22,240 new cases of ovarian cancer (OC) will be diagnosed in the United States and more than 14,000 individuals will die of the disease, making it the most lethal of the various gynecologic cancers. As with many other tumors, patient outcomes are critically dependent upon effective multidisciplinary care, which often includes contributions from gynecologic, medical and radiation oncologists as well as pathologists, diagnostic radiologists, oncology nurses and psychosocial services. In addition to the disease- and treatment-related morbidity and mortality associated with OC, pain, fatigue, lymphedema, depression/anxiety, infertility/childbearing and sexual dysfunction are commonly occurring issues that must also be addressed in the care of these patients.

    These video proceedings from a CME symposium held during the Society of Gynecologic Oncology’s 2018 Annual Meeting on Women’s Cancer explore significant therapeutic advances in the field of OC treatment by using the perspectives of leading experts on challenging cases and questions submitted by gynecologic and medical oncologists in the community to frame a relevant discussion of how this information has aided in the refinement of current routine clinical practice and ongoing research. This CME activity will help gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers find answers to the individualized questions and concerns that they frequently encounter and in turn provide high-quality cancer care.


    • Review available efficacy and safety data with the use of neoadjuvant chemotherapy followed by surgical cytoreduction for patients with Stage IIIC or IV OC, and identify patients who may be suitable for this approach.
    • Summarize existing research data and ongoing clinical trials documenting the risks and benefits of angiogenesis inhibition in the management of newly diagnosed advanced OC, and identify individuals who may benefit from this treatment strategy.
    • Develop a treatment algorithm for the management of progressive epithelial OC, considering the response to prior therapy, genomic profile, goals of treatment and the relative efficacy and safety of evidence-based therapeutic strategies.
    • Recognize the toxicities associated with therapeutic agents and regimens commonly used in the care of patients with OC, and offer supportive management strategies to minimize and/or ameliorate these side effects.
    • Develop an understanding of the mechanisms of action, available data and potential clinical roles of compounds under investigation for patients with advanced OC in preparation for their potential introduction into clinical practice.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Don S Dizon, MD
    Director, Women’s Cancers
    Lifespan Cancer Institute
    Director, Medical Oncology
    Rhode Island Hospital
    Associate Professor of Medicine
    Alpert Medical School of Brown University
    Providence, Rhode Island

    Consulting Agreement: Fujibio.

    Lainie P Martin, MD
    Chief, Gynecologic Medical Oncology
    Assistant Professor, Department of Hematology/Oncology
    Fox Chase Cancer Center
    Philadelphia, Pennsylvania

    Advisory Committee: ImmunoGen Inc, Tesaro Inc; Contracted Research: Novartis.

    Bradley J Monk, MD
    Division of Gynecologic Oncology
    Arizona Oncology (US Oncology Network)
    University of Arizona College of Medicine - Phoenix
    Creighton University School of Medicine at St Joseph’s Hospital
    Phoenix, Arizona

    Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Genentech, Incyte Corporation, Merck, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Genentech, Janssen Biotech Inc, Roche Laboratories Inc.

    Angeles Alvarez Secord, MD, MHSc
    Department of Obstetrics and Gynecology
    Division of Gynecologic Oncology
    Duke Cancer Institute
    Durham, North Carolina

    Advisory Committee: Alexion Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, Janssen Biotech Inc, Myriad Genetic Laboratories Inc, Roche Laboratories Inc, Tesaro Inc; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Merck.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Genentech, ImmunoGen Inc and Merck.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: May 2018
    Expiration date: May 2019

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):


Local and Systemic Therapeutic Considerations for Patients with Newly Diagnosed Advanced Ovarian Cancer (OC)

Evolving Treatment Paradigms for Patients with Platinum-Sensitive Recurrent OC

Patient- and Disease-Specific Considerations in the Management of Platinum-Resistant Recurrent OC

Novel Investigational Agents in Development for Patients with OC

Select Publications